-
-
-
-
-
-
-
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress
-
-
-
-
-
-
-
Aurinia Pharmaceuticals (AUPH) Tops Q1 EPS by 5c, provides guidance
-
-
-
-
-
-
-
Aurinia Pharmaceuticals (AUPH) Shareholder Calls for CEO Peter Greenleaf, Dr. Brinda Balakrishnan, and Dr. Robert Foster to Resign from the Board
-
-
-
-
-
-
-
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
-
-
-
-
-
-
-
After-hours movers: Aurinia Pharma gains on possible sale, Nike falls on earnings
-
-
-
-
-
-
-
Aurinia Pharmaceuticals (AUPH) Misses Q2 EPS by 3c
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Aurinia, Stronghold, Lilium, and Li-Cycle and Encourages Investors to Contact the Firm
-
1,233,809 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


